Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 8Esophageal Squamous Cell Carcinoma 4Pancreatic Neoplasms 2NSCLC 2Carcinoma, Squamous Cell 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pathologic Complete Response 1PFS 1Neoplasms 1NRG1-fused Non-small Cell Lung Cancer 1Gastrointestinal Neoplasms 1Focus of Study Instead 1EGFR Mutation Positive Non-small Cell Lung Cancer 1Colorectal Neoplasms 1Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Bevacizumab 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × PFS × Afatinib × Clear all
NCT05267288 2023-03-29

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Qingdao Central Hospital

Phase 2 Unknown
30 enrolled

PFS

Data powered by HemOnc (CC BY 4.0) Colophon âš¡